Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells
- PMID: 37788596
- PMCID: PMC10551551
- DOI: 10.1016/j.optom.2023.100481
Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells
Abstract
Purpose: To investigate the effect of benzalkonium chloride (BAK)-preserved latanoprost and bimatoprost, polyquad (PQ)-preserved travoprost, and preservative-free (PF) latanoprost and tafluprost, all prostaglandin analogues (PGAs), on human conjunctival goblet cell (GC) survival. Furthermore, to investigate the effect of BAK-preserved and PF latanoprost on the cytokine secretion from GC.
Methods: Primary human conjunctival GCs were cultivated from donor tissue. Lactate dehydrogenase (LDH) and tetrazolium dye colorimetric (MTT) assays were used for the assessment of GC survival. A cytometric bead array was employed for measuring secretion of interleukin (IL)-6 and IL-8 from GC.
Results: BAK-preserved latanoprost and bimatoprost reduced cell survival by 28% (p = 0.0133) and 20% (p = 0.0208), respectively, in the LDH assay compared to a negative control. BAK-preserved latanoprost reduced cell proliferation by 54% (p = 0.003), BAK-preserved bimatoprost by 45% (p = 0.006), PQ-preserved travoprost by 16% (p = 0.0041), and PF latanoprost by 19% (p = 0.0001), in the MTT assay compared to a negative control. Only PF tafluprost did not affect the GCs in either assay. BAK-preserved latanoprost caused an increase in the secretion of pro-inflammatory IL-6 and IL-8 (p = 0.0001 and p = 0.0019, respectively) compared to a negative control, which PF latanoprost did not.
Conclusion: BAK-preserved PGA eye drops were more cytotoxic to GCs than PQ-preserved and PF PGA eye drops. BAK-preserved latanoprost induced an inflammatory response in GC. Treatment with PF and PQ-preserved PGA eye drops could mean better tolerability and adherence in glaucoma patients compared to treatment with BAK-preserved PGA eye drops.
Keywords: Benzalkonium chloride; Conjunctival goblet cells; Polyquad; Preservative-free; Prostaglandin analogue.
Copyright © 2023 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest MK and SH have received funding from Laboratoires Théa (France) for other studies. Otherwise, there are no competing interests in relation to this study.
Figures




Similar articles
-
The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.Acta Ophthalmol. 2023 Dec;101 Suppl 278:3-21. doi: 10.1111/aos.15808. Acta Ophthalmol. 2023. PMID: 38037546
-
Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties.Acta Ophthalmol. 2022 Nov;100(7):819-827. doi: 10.1111/aos.15163. Epub 2022 May 8. Acta Ophthalmol. 2022. PMID: 35527390 Free PMC article.
-
Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.Curr Eye Res. 2011 Nov;36(11):979-88. doi: 10.3109/02713683.2011.578781. Curr Eye Res. 2011. PMID: 21999224
-
Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.Adv Ther. 2012 Oct;29(10):874-88. doi: 10.1007/s12325-012-0057-1. Epub 2012 Oct 10. Adv Ther. 2012. PMID: 23065664
-
Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.J Glaucoma. 2014 Jan;23(1):e69-75. doi: 10.1097/IJG.0b013e3182a075e6. J Glaucoma. 2014. PMID: 23881267
Cited by
-
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.Pharmaceutics. 2025 Mar 31;17(4):447. doi: 10.3390/pharmaceutics17040447. Pharmaceutics. 2025. PMID: 40284442 Free PMC article. Review.
References
-
- 5th ed. European Glaucoma Society; 2020. Terminology and Guidelines for Glaucoma.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous